A double- Blind placebo-controlled study of lamotriqine monotherapy outpatients with bipolar I depression

J. R. Calabrese, C. L. Bowden, G. S. Sachs, J. A. Ascher, E. Monaghan, G. O. Rudd

Research output: Contribution to journalArticle

Abstract

Background: More treatment options for bipolar depression are needed. Currently available antidepressants may increase the risk of mania and rapid cycling, and mood stabilizers appear to be less effective in treating depression than mania. Preliminary data suggest that lamotrigine, an established antiepileptic drug, may be effective for both the depression and mania associated with bipolar disorder. This is the first controlled multicenter study evaluating lamotrigine monotherapy in the treatment of bipolar I depression. Methods: Outpatients with bipolar I disorder experiencing a major depressive episode (DSM-IV, N = 195) received lamotrigine (50 or 200mg/day) or placebo as monotherapy for 7 weeks. Psychiatric evaluations, including the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), Mania Rating Scale, and the Clinical Global Impressions scale for Severity (CGI-S) and Improvement (CGI-I) were completed at each weekly visit. Results: Lamotrigine 200mg/day demonstrated significant antidepressant efficacy on the 17-item HAM-D, HAM-D Item 1, MADRS, CGI-S, and CGI-I compared with placebo. Improvements were seen as early as Week 3. Lamotrigine 50mg/day also demonstrated efficacy compared with placebo on several measures. The proportions of patients exhibiting a response on CGI-I were 51 percent, 41 percent, and 26 percent for lamotrigine 200mg/day, lamotrigine SOmg/day, and placebo groups, respectively. Adverse events and other safety results were similar across treatment groups, except for a higher rate of headache in the lamotrigine groups. Conclusion: Lamotrigine monotherapy is an effective and well-tolerated treatment for bipolar depression.

Original languageEnglish (US)
Pages (from-to)165-166
Number of pages2
JournalHeadache Quarterly
Volume10
Issue number2
StatePublished - Dec 1 1999

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A double- Blind placebo-controlled study of lamotriqine monotherapy outpatients with bipolar I depression'. Together they form a unique fingerprint.

  • Cite this

    Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., & Rudd, G. O. (1999). A double- Blind placebo-controlled study of lamotriqine monotherapy outpatients with bipolar I depression. Headache Quarterly, 10(2), 165-166.